Latest filing published 14 Oct 2026 for Cue Biopharma, Inc., €29k.
Filing timeline
BuySaleInsider track record
Michael Vincent Meluzio: trading record in brief
Michael Vincent Meluzio discloses dealings in Cue Biopharma, Inc. to SEC (Form 4). The record holds 6 filings, for trades running from 9 July 2026 to 12 October 2026.
Sales make up the whole of the open-market record (4 sales, €175k). The rest of the record consists of 1 share grant and 1 option exercise.
The latest filing, published on 14 October 2026, reports an open-market sale of €29k in Cue Biopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Michael Vincent Meluzio
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,144 shares@ US$28.05Common StockSEC:0002138368-26-000009:0
- 13,647 shares0Common StockSEC:0002138368-26-000007:0
- 4,106 shares@ US$30.350.054% mcap73.6% of flowCommon StockSEC:0002138368-26-000007:2
- 3 shares@ US$31.130.0000% mcap0.1% of flowCommon StockSEC:0002138368-26-000007:3
- 1,519 shares@ US$29.370.019% mcap26.3% of flowCommon StockSEC:0002138368-26-000007:1
- 40,942 shares0Common StockSEC:0002138368-26-000005:0
6 of 6 declarations
